J.P. Morgan analyst Jessica Fye has maintained their bullish stance on VRTX stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 10:30 AM ETCompany ParticipantsDr.

Orna will receive a $65m upfront payment and is eligible to receive potential milestone payments and royalties.

A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com, in the "Investors" section under the "News and Events" page. A replay of the conference webcast will ...

Piper Sandler analyst Christopher Raymond maintained a Buy rating on Cogent Biosciences (COGT – Research Report) today and set a price target ...

The "CRISPR-based Gene Editing Market by Product & Service, by Application, by End-User, and By Region" report has been added ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

These generic granules are equivalent to Vertex Pharmaceuticals' 'Kalydeco' oral granules in the same strengths.

EY—the professional services firm originally known as Ernst & Young—reports the dollar value of biopharma M&A deals nosedived ...

This Fool has his eye on an innovative growth stock that has plunged by 80% since early 2021. But what is so special about it ...

India has the potential to increase exports of organic products up to Rs 20,000 crore in the next three years, Commerce and ...